AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Efficacy and Safety of Pitavastatin Plus Ezetimibe versus Pitavastatin Monotherapy in Adults with Hypercholesterolemia

By Siddiqui ZH, Habiba U, Faisal N et al.

Objective: To evaluate the efficacy and safety of pitavastatin plus ezetimibe compared with pitavastatin monotherapy in adults with hypercholesterolemia or dyslipidemia. Methods: A systematic review and meta-analysis of randomized controlled trials was conducted according to PRISMA guidelines and registered in PROSPERO (CRD420251028759). PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched from inception to April 2026 for randomized trials comparing pitavastatin plus ezetimibe with pitavastatin monotherapy in adults with hypercholesterolemia or dyslipidemia. Continuous outcomes were pooled as mean differences (MD) and dichotomous outcomes as risk ratios (RR) using a random-effects model. Results: Four randomized controlled trials involving 2,403 participants were included. Compared with pitavastatin monotherapy, pitavastatin plus ezetimibe significantly reduced LDL-C levels (MD –22.54 mg/dL; 95% CI –25.47 to –19.61; I ² = 69%), with moderate to high heterogeneity across studies. Combination therapy also significantly reduced total cholesterol, while no significant differences were observed for HDL-C or triglyceride levels. The incidence of overall adverse events was similar between treatment groups (RR 1.05; 95% CI 0.89-1.25; I ² = 0%). Conclusion: Pitavastatin plus ezetimibe provides greater reductions in LDL-C and total cholesterol compared with pitavastatin monotherapy without increasing adverse events. These findings suggest that combination therapy is an effective and well-tolerated strategy for lipid lowering in adults with hypercholesterolemia or dyslipidemia.

doi.org/10.1161/circ.154.suppl_1.16941Interventions

AgingResearch.News